UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
SeraCare Life Sciences, Inc.
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
(CUSIP Number)
|
Martin Shkreli
MSMB Capital Management, LLC
330 Madison Ave., 6th floor
New York, NY 10017
(646) 495 - 5073
|
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box
¨
.
Note
: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.
See
§ 240.13d-7 for other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 11 Pages)
The Schedule 13D (the “Schedule 13D”) filed on July 12, 2011 by Bloomfield Partners LP (“Bloomfield”), Pompeii Management, LLC (“Pompeii”), MSMB Capital Management, LLC (“MSMB Capital”), MSMB Healthcare LP (“MSMB Healthcare”), MSMB Healthcare Investors LLC (“MSMB Investors”), MSMB Healthcare Management LLC (“MSMB Management”) and Martin Shkreli (collectively, the “Reporting Persons”), with respect to the common stock, par value $0.001 per share (the “Common Stock”) of SeraCare Life Sciences, Inc. (the “Issuer”), is hereby amended by this Amendment No. 1. Only those items hereby reported in this Amendment No. 1 are amended and all other items remain unchanged. Terms used herein but not otherwise defined herein shall have the meanings ascribed thereto in the Schedule 13D.
Item 5. Interest in Securities of the Issuer.
Items 5(a), 5(b), 5(c) and 5(e) of the Schedule 13D are amended and restated to read as follows:
(a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 0 shares of Common Stock, representing 0.00% of the Issuer’s outstanding Common Stock.
(b) Each of the Reporting Persons has sole voting power and sole dispositive power with regard to 0 shares of Common Stock and shared voting power and shared dispositive power with regard to 0 shares of Common Stock.
(c) During the past 60 days, the Reporting Persons made open market sales of an aggregate of 996,723 shares of Common Stock on February 14, 2012, for an average price per share of $3.95.
(e) As of February 14, 2012, the Reporting Persons ceased to be the beneficial owners of more than 5% of the Common Stock of the Issuer.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 22, 2012
BLOOMFIELD PARTNERS LP
/s/ Martin Shkreli
Name: Martin Shkreli
Title: Authorized Person
POMPEII MANAGEMENT, LLC
/s/ Martin Shkreli
Name: Martin Shkreli
Title: Authorized Person
MSMB CAPITAL MANAGEMENT, LLC
/s/ Martin Shkreli
Name: Martin Shkreli
Title: Managing Member
MSMB HEALTHCARE LP
By MSMB Healthcare Investors LLC, its general partner
/s/ Martin Shkreli
Name: Martin Shkreli
Title: Managing Member
MSMB HEALTHCARE INVESTORS LLC
/s/ Martin Shkreli
Name: Martin Shkreli
Title: Managing Member
MSMB HEALTHCARE MANAGEMENT LLC
/s/ Martin Shkreli
Name: Martin Shkreli
Title: Managing Member
/s/ Martin Shkreli
Martin Shkreli